← All trials
NCT05848687
Phase 1/Phase 2Interventional
Trials that are a combination of phases 1 and 2.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2023
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2033
- First posted
- May 8, 2023
- Last posted
- Sep 13, 2023
- Enrollment
- 90
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Stanford UniversityLead sponsor
- AmgenCollaborator
- Pediatric Oncology Experimental Therapeutics Investigation ConsortiumCollaborator
- Stanford UniversityOverall official - principal investigator
- Kura Oncology, Inc.Collaborator
- Stanford UniversitySponsor investigator
- Stanford UniversityOfficial
- Department of DefenseCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.